Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor

Transplantation Proceedings

Volumn 46, Issue 4, 2014, Pages 1226-1228

  Wu, M J ^a,b,c,d,e,g   Chang, C H ^f   Shu, K H ^a,b   Ho, H C ^a   Li, J R ^a   Fu, Y C ^a,f  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (China)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e TUNGHAI UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g Department of Life Science Tunghai University ^*

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; INTEGRIN LINKED KINASE; RAPAMYCIN; UROKINASE RECEPTOR; FOCAL ADHESION KINASE 1; IMMUNOSUPPRESSIVE AGENT; INTEGRIN-LINKED KINASE; PLAUR PROTEIN, RAT; PROTEIN SERINE THREONINE KINASE; PTK2 PROTEIN, RAT;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; CELL DEATH; CELL MIGRATION; CELL STRUCTURE; CELL VIABILITY; CONFERENCE PAPER; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL MOTION; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; PROTEINURIA; SIGNAL TRANSDUCTION; TIME; TOXICITY; WISTAR RAT;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FOCAL ADHESION KINASE 1; IMMUNOSUPPRESSIVE AGENTS; PODOCYTES; PRIMARY CELL CULTURE; PROTEIN-SERINE-THREONINE KINASES; PROTEINURIA; RATS, WISTAR; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; UP-REGULATION;

EID: 84900324248     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.12.011     Document Type: Conference Paper

References (12)

1. B.D. Kahan Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study Lancet 356 2000 194 202
2. M.J. Wu, K.H. Shu, and J.D. Lian et al. Impact of variability of sirolimus trough level on chronic allograft nephropathy Transplant Proc 40 2008 2202 2205
3. A. Liew, G.S. Chiang, and A. Vathsala Factors associated with proteinuria in renal transplant recipients treated with sirolimus Transpl Int 22 2009 313 322
4. H. Izzedine, I. Brocheriou, and C. Frances Post-transplantation proteinuria and sirolimus N Engl J Med 353 2005 2088 2089
5. L. Biancone, B. Bussolati, and G. Mazzucco et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy Am J Transplant 10 2010 2270 2278
6. E. Letavernier, P. Bruneval, and C. Mandet et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo Clin J Am Soc Nephrol 2 2007 326 333
7. C. Wei, C.C. Möller, and M.M. Altintas et al. Modification of kidney barrier function by the urokinase receptor Nat Med 14 2008 55 63
8. E. Letavernier, P. Bruneval, and S. Vandermeersch et al. Sirolimus interacts with pathways essential for podocyte integrity Nephrol Dial Transplant 24 2009 630 638
9. J. Patrakka, and K. Tryggvason New insights into the role of podocytes in proteinuria Nat Rev Nephrol 5 2009 463 468
10. H.W. Smith, and C.J. Marshall Regulation of cell signalling by uPAR Nat Rev Mol Cell Biol 11 2010 23 36
11. B. Vollenbröker, B. George, and M. Wolfgart et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes Am J Physiol Renal Physiol 296 2009 F418 F426
12. H. Ma, A. Togawa, and K. Soda et al. Inhibition of podocyte FAK protects against proteinuria and foot process effacement J Am Soc Nephrol 21 2010 1145 1156